Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomasOn track to init...
Salt Lake City United States Chris Gibson Development Expenses Recursion Pharmaceuticals Inc European Commission
Source: businessinsider.com